---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-033014"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2023-09-26T23:59:59+00:00"
generated_at: "2026-06-10T08:32:33.191337+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology reports positive Phase 2 data for onvansertib in pancreatic and lung cancers

## Summary
- mPDAC Phase 2: ORR 19% (1 confirmed PR, 3 pending) vs historical 7.7%; mPFS 5.0 mo vs 3.1 mo.
- Biomarker trial: single-agent onvansertib reduced Ki67 by 86% and CA19-9 by 28% in refractory mPDAC.
- Plans first-line mPDAC investigator-initiated trial of onvansertib + Gemzar/Abraxane at OHSU.
- SCLC Phase 2: preliminary single-agent activity; safety confirmed; trial continues enrolling.
- Conference call scheduled for Sept 26, 2023 at 5pm ET to discuss data.

## SEC filing metadata
- accession: 0001628280-23-033014
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2023-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000162828023033014/0001628280-23-033014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000162828023033014/crdf-20230926.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-033014
- JSON: https://secwatch.observer/filing/0001628280-23-033014.json
- Plain text: https://secwatch.observer/filing/0001628280-23-033014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.